Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia

Current Oncology Reports

Volumn 5, Issue 6, 2003, Pages 489-497

  Meshinchi, Soheil ^b   Smith, Franklin O ^b   Arceci, Robert J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MYELOABLATIVE AGENT; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER THERAPY; CHILD; HIGH RISK PATIENT; HUMAN; OUTCOMES RESEARCH; PROGNOSIS; RECURRENCE RISK; REVIEW; TREATMENT PLANNING; ACUTE DISEASE; HISTOCOMPATIBILITY; MYELOID LEUKEMIA; RISK FACTOR; STEM CELL TRANSPLANTATION; TUMOR RECURRENCE;

ACUTE DISEASE; ANTINEOPLASTIC AGENTS; CHILD; HISTOCOMPATIBILITY; HUMANS; LEUKEMIA, MYELOID; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RISK FACTORS; STEM CELL TRANSPLANTATION;

EID: 2442516280     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-003-0010-1     Document Type: Review

References (83)

1. Webb DK, Wheatley K, Harrison G, et al.: Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party. Leukemia 1999, 13:25-31.
2. Wheatley K, Burnett AK, Goldstone AH, et al.: A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999, 107:69-79.
3. Davies SM, Alonzo TA, Lange B, et al.: Reduced survival in black children with acute myeloid leukemia [abstract]. Blood 2002, 91:122(a).
4. Drabkin HA, Erickson P: Down syndrome and leukemia: an update. Prog Clin Biol Res 1995, 393:169-176.
5. Creutzig U, Ritter J, Ludwig WD, et al.: Acute myeloid leukemia in children with Down syndrome. Klin Padiatr 1995, 207:136-144.
6. Ravindranath Y, Abella E, Krischer JP, et al.: Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood 1992, 80:2210-2214.
7. Davies SM, Robison LL, Buckley JD, et al.: Glutathione S-transferase polymorphisms in children with myeloid leukemia: a Children's Cancer Group study. Cancer Epidemiol Biomarkers Prev 2000, 9:563-566.
8. Creutzig U, Zimmermann M, Ritter J, et al.: Definition of a standard-risk group in children with AML. Br J Haematol 1999, 104:630-639.
9. Raimondi SC, Chang MN, Ravindranath Y, et al.: Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative Pediatric Oncology Group study-POG 8821. Blood 1999, 94:3707-3716.
10. Martinez-Climent JA, Espinosa R III, Thirman MJ, et al.: Abnormalities of chromosome band 11q23 and the MLL gene in pediatric myelomonocytic and monoblastic leukemias: identification of the t(9, 11) as an indicator of long survival. J Pediatr Hematol Oncol 1995, 17:277-283.
11. Kalwinsky DK, Raimondi SC, Schell MJ, et al.: Prognostic importance of cytogenetic subgroups in de novo pediatric acute nonlymphocytic leukemia. J Clin Oncol 1990, 8:75-83.
12. Lowenberg B, Downing JR, Burnett A: Acute myeloid leukemia. N Engl J Med 1999, 341:1051-1062.
13. Downing JR: The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: biology and clinical significance. Br J Haematol 1999, 106:296-308.
14. Byrd JC, Dodge RK, Carroll A, et al.: Patients with t(8, 21) (q22,q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 1999, 17:3767-3775.
15. Chang M, Raimondi SC, Ravindranath Y, et al.: Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821. Leukemia 2000, 14:1201-1207.
16. Grimwade D, Walker H, Oliver F, et al.: The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92:2322-2333.
17. Webb DK, Harrison G, Stevens RF, et al.: Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood 2001, 98:1714-1720.
18. Stevens RF, Hann IM, Wheatley K, Gray RG: Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol 1998, 101:130-140.
19. Wells RJ, Arthur DC, Srivastava A, et al.: Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213. Leukemia 2002, 16:601-607.
20. Rubnitz JE, Raimondi SC, Tong X, et al.: Favorable impact of the t(9, 11) in childhood acute myeloid leukemia. J Clin Oncol 2002, 20:2302-2309.
21. Felix CA, Hosler MR, Winick NJ, et al.: ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children. Blood 1995, 85:3250-3256.
22. Hilden JM, Smith FO, Frestedt JL, et al.: MLL gene rearrangement, cytogenetic 11q23 abnormalities, and expression of the NG2 molecule in infant acute myeloid leukemia. Blood 1997, 89:3801-3805.
23. Martinez-Climent JA, Thirman MJ, Espinosa R III, et al.: Detection of 11q23/MLL rearrangements in infant leukemias with fluorescence in situ hybridization and molecular analysis. Leukemia 1995, 9:1299-1304.
24. Coustan-Smith E, Behm FG, Sanchez J, et al.: Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998, 351:550-554.
25. Martinez-Climent JA, Lane NJ, Rubin CM, et al.: Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia de novo. Leukemia 1995, 9:95-101.
26. Weiner HL, Zagzag D: Growth factor receptor tyrosine kinases: cell adhesion kinase family suggests a novel signaling mechanism in cancer. Cancer Invest 2000, 18:544-554.
27. Stephenson SA, Slomka S, Douglas EL, et al.: Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer. BMC Mol Biol 2001, 2:15.
28. Wiener JR, Kassim SK, Yu Y, et al.: Transfection of human ovarian cancer cells with the HER-2/neu receptor tyrosine kinase induces a selective increase in PTP-H1, PTP-1B, PTP-alpha expression. Gynecol Oncol 1996, 61:233-240.
29. Tsujimura T, Kanakura Y, Kitamura Y: Mechanisms of constitutive activation of c-kit receptor tyrosine kinase. Leukemia 1997, 11(Suppl 3):396-398.
30. Turner AM, Lin NL, Issarachai S, et al.: FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells. Blood 1996, 88:3383-3390.
31. Padua RA, Guinn BA, Al-Sabah AI, et al.: RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia 1998, 12:887-892.
32. Gille H, Kowalski J, Li B, et al.: Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2): a reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 2001, 276:3222-3230.
33. Aguayo A, Estey E, Kantarjian H, et al.: Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999, 94:3717-3721.
34. Bos JL: Ras oncogenes in human cancer: a review. Cancer Res 1989, 49:4682-4689.
35. Kubo K, Naoe T, Kiyoi H, et al.: Clonal analysis of multiple point mutations in the N-ras gene in patients with acute myeloid leukemia. Jpn J Cancer Res 1993, 84:379-387.
36. Towatari M, Iida H, Tanimoto M, et al.: Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells. Leukemia 1997, 11:479-484.
37. Kiyoi H, Towatari M, Yokota S, et al.: Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998, 12:1333-1337.
38. Yamamoto Y, Kiyoi H, Nakano Y, et al.: Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001, 97:2434-2439.
39. Kiyoi H, Naoe T, Nakano Y, et al.: Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999, 93:3074-3080.
40. Kondo M, Horibe K, Takahashi Y, et al.: Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. Med Pediatr Oncol 1999, 33:525-529.
41. Meshinchi S, Woods WG, Stirewalt DL, et al.: Prevalence and prognostic significance of flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001, 97:89-94.
42. Longley BJ Jr, Metcalfe DD, Tharp M, et al.: Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A 1999, 96:1609-1614.
43. Nagata H, Worobec AS, Oh CK, et al.: Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 1995, 92:10560-10564.
44. Ridge SA, Worwood M, Oscier D, et al.: FMS mutations in myelodysplastic, leukemic, and normal subjects. Proc Natl Acad Sci U S A 1990, 87:1377-1380.
45. Ning ZQ, Li J, Arceci RJ: Activating mutations of c-kit at codon 816 confer drug resistance in human leukemia cells. Leuk Lymphoma 2001, 41:513-522.
46. Radich JP, Kopecky KJ, William CL, et al.: N-Ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance. Blood 1990, 76:801-807.
47. Meshinchi S, Stirewalt DL, Alonzo TA, et al.: Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood 2003, 102:1474-1479.
48. Stirewalt DL, Kopecky KJ, Meshinchi S, et al.: FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 2001, 97:3589-3595.
49. Kottaridis PD, Gale RE, Frew ME, et al.: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001, 98:1752-1759.
50. Thiede C, Steudel C, Mohr B, et al.: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 99:4326-4335.
51. Zwaan CM, Meshinchi S, Radich JP, et al.: FLT3 internal tandem duplication in 234 children with acute myeloid leukemia (AML): prognostic significance and relation to cellular drug resistance. Blood 2003 June 19 [epub].
52. Thiede C, M S, U S, et al.: Quantitative determination of Flt3 internal tandem duplication (ITD) mutations defines a subgroup with poor prognosis in standard risk AML [abstract 2334]. Presented at the annual meeting of the American Society of Hematology. San Francisco, CA. December 2-5, 2000.
53. Whitman SP, Archer KJ, Feng L, et al.: Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a Cancer and Leukemia Group B study. Cancer Res 2001, 61:7233-7239.
54. Viehmann S, Teigler-Schlegel A, Bruch J, et al.: Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement. Leukemia 2003, 17:1130-1136.
55. Tobal K, Newton J, Macheta M, et al.: Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8,21) can identify patients in durable remission and predict clinical relapse. Blood 2000, 95:815-819.
56. Buonamici S, Ottaviani E, Testoni N, et al.: Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. Blood 2002, 99:443-449.
57. Miller WH Jr, Levine K, DeBlasio A, et al.: Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA. Blood 1993, 82:1689-1694.
58. Grimwade D, Lo Coco F: Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia 2002, 16:1959-1973.
59. Mandelli F, Diverio D, Avvisati G, et al.: Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997, 90:1014-1021.
60. Nucifora G, Larson RA, Rowley JD: Persistence of the 8, 21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 1993, 82:712-715.
61. Grimwade D: Screening for core binding factor gene rearrangements in acute myeloid leukemia. Leukemia 2002, 16:964-969.
62. San Miguel JF, Vidriales MB, Lopez-Berges C, et al.: Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001, 98:1746-1751.
63. Sievers EL, Lange BJ, Alonzo TA, et al.: Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood 2003, 101:3398-3406.
64. Preudhomme C, Sagot C, Boissel N, et al.: Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 2002, 100:2717-2723.
65. Pabst T, Mueller BU, Zhang P, et al.: Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 2001, 27:263-270.
66. Verstovsek S, Manshouri T, Smith FO, et al.: Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia. Cancer 2003, 97:2212-2217.
67. de Bont ES, Fidler V, Meeuwsen T, et al.: Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clin Cancer Res 2002, 8:2856-2861.
68. Golub TR, Slonim DK, Tamayo P, et al.: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286:531-537.
69. Alizadeh AA, Eisen MB, Davis RE, et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
70. Shipp MA, Ross KN, Tamayo P, et al.: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002, 8:68-74.
71. Rosenwald A, Wright G, Chan WC, et al.: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:1937-1947.
72. Pomeroy SL, Tamayo P, Gaasenbeek M, et al.: Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002, 415:436-442.
73. van't Veer LJ, Dai H, van de Vijver MJ, et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
74. Yeoh EJ, Ross ME, Shurtleff SA, et al.: Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002, 1:133-143.
75. Beer DG, Kardia SL, Huang CC, et al.: Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002, 8:816-824.
76. Yagi T, Morimoto A, Eguchi M, et al.: Identification of a gene expression signature associated with prognosis of pediatric AML. Blood 2003, 102:1849-1856.
77. Odom LF, Gordon EM: Acute monoblastic leukemia in infancy and early childhood: successful treatment with an epipodophyllotoxin. Blood 1984, 64:875-882.
78. Nishikawa A, Nakamura Y, Nobori U, et al.: Acute monocytic leukemia in children: response to VP-16-213 as a single agent. Cancer 1987, 60:2146-2149.
79. Krance RA, Hurwitz CA, Head DR, et al.: Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol 2001, 19:2804-2811.
80. Chen AR, Alonzo TA, Woods WG, Arceci RJ: Current controversies: Which patients with acute myeloid leukaemia should receive a bone marrow transplantation? An American view. Br J Haematol 2002, 118:378-384.
81. Burnett AK, Wheatley K, Goldstone AH, et al.: The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002, 118:385-400.
82. Creutzig U, Reinhardt D: Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? A European view. Br J Haematol 2002, 118:365-377.
83. Woods WG, Neudorf S, Gold S, et al.: A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001, 97:56-62.